At close: September 27 at 4:00 PM EDT
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | 1 | 2 | 2 |
| Avg. Estimate | 0 | -1.5 | -2.42 | -1.92 |
| Low Estimate | 0 | -1.5 | -2.99 | -2.04 |
| High Estimate | 0 | -1.5 | -1.85 | -1.8 |
| Year Ago EPS | -- | -- | -2.09 | -2.42 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | 1 | 2 | 2 |
| Avg. Estimate | -- | 1.25M | 4.53M | 13.63M |
| Low Estimate | -- | 1.25M | 3.14M | 1.3M |
| High Estimate | -- | 1.25M | 5.91M | 25.97M |
| Year Ago Sales | -- | -- | 7.8M | 4.53M |
| Sales Growth (year/est) | -- | -- | -41.90% | 200.90% |
Earnings History
| CURRENCY IN USD | 12/31/2022 | 6/30/2024 | ||
|---|---|---|---|---|
| EPS Est. | -- | -- | -1 | -1.49 |
| EPS Actual | -- | -- | -0.6 | -0.54 |
| Difference | -- | -- | 0.4 | 0.95 |
| Surprise % | -- | -- | 40.00% | 63.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | -1.5 | -2.42 | -1.92 |
| 7 Days Ago | 0 | -1.49 | -2.41 | -1.91 |
| 30 Days Ago | 0 | -1.51 | -2.44 | -1.93 |
| 60 Days Ago | 0 | -1.43 | -2.24 | -1.57 |
| 90 Days Ago | 0 | -1.41 | -2.21 | -1.55 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | MOLN | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 5.60% |
| Next Qtr. | -- | -- | -- | 9.90% |
| Current Year | -15.80% | -- | -- | 3.40% |
| Next Year | 20.70% | -- | -- | 12.70% |
| Next 5 Years (per annum) | -- | -- | -- | 11.90% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Maintains | JP Morgan: Neutral to Neutral | 12/5/2023 |
| Downgrade | SVB Leerink: Outperform to Market Perform | 8/29/2022 |
| Upgrade | Credit Suisse: Underperform to Neutral | 5/25/2022 |
| Maintains | SVB Leerink: Outperform | 4/27/2022 |
| Maintains | SVB Leerink: Outperform | 1/14/2022 |
| Maintains | SVB Leerink: Outperform | 8/27/2021 |
Related Tickers
LSB LakeShore Biopharma Co., Ltd
0.8373
+6.66%
SPAGO.ST Spago Nanomedical AB (publ)
0.2480
+3.33%
2CUREX.ST 2cureX AB (publ)
0.6550
-0.76%
ZSB.F Sirona Biochem Corp.
0.0355
-7.79%
OBIO Orchestra BioMed Holdings, Inc.
5.02
+3.93%
APLM Apollomics, Inc.
0.1310
-1.50%
ADXN.SW Addex Therapeutics Ltd
0.0690
-4.96%
APLMW Apollomics, Inc.
0.0108
0.00%
LSBPW LakeShore Biopharma Co., Ltd
0.0601
-13.28%
DNTH Dianthus Therapeutics, Inc.
27.24
+0.81%